Results 1 to 10 of about 6,111 (204)
Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study [PDF]
BMC Neurology, 2020 Background Compared with embolic occlusions, intracranial atherosclerotic stenosis (ICAS)-related large vessel occlusions (LVOs) often require rescue treatment following mechanical thrombectomy (MT).
Yong-Won Kim +11 more
doaj +4 more sources
Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Approximately half of patients who achieve successful reperfusion do not achieve functional independence. The present study sought to investigate the clinical outcomes and safety of intraarterial or intravenous tirofiban as adjunct therapy in ...
Huagang Li +12 more
doaj +5 more sources
Effects of tirofiban on haemostatic activation in vitro [PDF]
British Journal of Anaesthesia, 2004 Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban ...
Jerrold H. Levy +5 more
openaire +4 more sources
Therapeutic efficiency of tirofiban in acute coronary syndromes [PDF]
The Lancet, 2000 William McConnell +4 more
+9 more sources
Tirofiban-induced thrombocytopenia
Annals of Medicine, 2023 Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. It reduces the incidence of thrombotic cardiovascular events in patients with non-ST-segment elevation acute coronary syndrome (NSTE ...
Jun Wang, Dongna Zou
openaire +3 more sources
Scientific Reports, 2021 Periprocedural antithrombotic management with glycoprotein IIb/IIIa inhibitors (GPI) for intracranial artery stenting is still controversial. We sought to assess the safety and efficacy of prophylactic tirofiban infusion for acute intracranial ...
Lili Sun +9 more
doaj +1 more source
Kaohsiung Journal of Medical Sciences, 2021 To investigate the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris (UA).
Li Deng +3 more
doaj +1 more source
Zhongguo shuxue zazhi, 2022 Objective To explore the feasibility of tirofiban, a platelet surface glycoprotein (GP)Ⅱb/Ⅲa receptor antagonist intervene in transfusion-related acute lung injury (TRALI), by inhibiting platelet activation and by preventing platelet and neutrophil ...
Xin YUAN +6 more
doaj +1 more source
Pakistan Journal of Health Sciences, 2023 Major Adverse Cardiovascular Events (MACE) and and Cerebrovascular Accidents (CVA) have become primary areas of interest due to the ongoing focal research in cardiovascular diseases. Objective: To assess the frequency of major adverse cardiac events and cerebrovascular accidents for intracoronary tirofiban and intravenous tirofiban. Methods: It was
Syed Husnain Raza Bukhari +5 more
openaire +1 more source
Frontiers in Neurology, 2021 Objective: To evaluate the efficacy and safety of tirofiban for patients with acute ischemic stroke (AIS), especially posterior circulation stroke (PCS).Methods: We enrolled consecutive patients with AIS who suffered large artery occlusion (LAO) and ...
Lingxin Cai +8 more
doaj +1 more source